NCT06990880 - A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 12, 2025

Primary Completion Date

October 26, 2027

Study Completion Date

August 9, 2028

Conditions

Neoplasms, Prostate

Interventions

DRUG

GSK5458514

GSK5458514 will be administered.

Trial Locations (5)

RECRUITING

GSK Investigational Site, Nashville

RECRUITING

GSK Investigational Site, Denver

RECRUITING

GSK Investigational Site, Montreal

RECRUITING

GSK Investigational Site, Tokyo

RECRUITING

GSK Investigational Site, Tokyo